Please assess the completion status of the following clinical trial:

Trial Title: Improved Strategies for Outpatient Opioid Detoxification

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Meets DSM-IV criteria for current opiate dependence disorder of at least six months duration, supported by urine toxicology OR COWS score \> or =6 OR Naloxone Challenge .~* Seeking treatment for opioid dependence.~* In otherwise good health based on complete medical history and physical examination~* Able to give written informed consent.~Exclusion Criteria:~* Methadone maintenance treatment or regular use of illicit methadone (\> 30 mg per week).~* Maintenance on, or regular use of buprenorphine or other long-acting narcotic agonists~* Active medical illness which might make participation hazardous, such as untreated hypertension, acute hepatitis with AST or ALT \> 3 times normal, AIDS, unstable diabetes.~* Severe psychiatric illness (psychotic disorder, major depression, suicide risk or 1 or more suicide attempts within the past year.)~* Physiologically dependent on alcohol or sedative-hypnotics~* History of allergic or adverse reaction to buprenorphine, naltrexone, naloxone, clonidine, or clonazepam.~* Chronic pain requiring opioid analgesia or anticipated surgery necessitating opioid medications~* AIDS dementia or other chronic organic mental disorder~* Pregnancy, lactation, failure to use contraception~* History of accidental drug overdose in the last 3 years as defined as an episode of opioid-induced unconsciousness or incapacitation, whether or not medical treatment was sought or received.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Buprenorphine (Type: ACTIVE_COMPARATOR): Standard 7-day buprenorphine induction and gradual taper from 8 mg to 0 mg followed on day 15 by Vivitrol injection
- Oral naltrexone (Type: ACTIVE_COMPARATOR): The naltrexone arm is a modification of our current inpatient naltrexone induction procedure, consisting of a single day of buprenorphine followed by a washout day and 4 days of ascending oral naltrexone doses. Followed on day 8 by Vivitrol injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).